Therapeutic role for bismuth compounds in TNBS-induced colitis in the rat

Digestive Diseases and Sciences

Volumn 45, Issue 3, 2000, Pages 466-473

  Peterson, T C ^a,b   Cleary, C E ^a   Shaw, A M ^a   Malatjalian, D A ^a   Veldhuyzen Van Zanten, S J O ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Bismuth; Colitis; TNBS

Indexed keywords

BISMUTH SALICYLATE; TRINITROBENZENESULFONIC ACID;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; INFLAMMATION; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; WOUND HEALING;

ANIMALS; ANTI-ULCER AGENTS; BISMUTH; COLITIS; FEMALE; MESALAMINE; ORGANOMETALLIC COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; SALICYLATES; TRINITROBENZENESULFONIC ACID;

EID: 0034109165     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005476619923     Document Type: Article

References (23)

1. 1. Marshall BJ: The use of bismuth in gastroenterology. Am J Gastroenterol 86:16-25, 1991
2. 2. Gorbach SL: Bismuth therapy in gastro-intestinal diseases. Gastroenterology 99:863-875, 1990
3. 3. Chiba N, Rao BV, Rademaker JW, et al: Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 87:1716-1727, 1992
4. 4. Srivastava ED, Swift GL, Wilkinson S, Williams GT, Evans BK, Rhodes J: Tripotassium dictrato bismuthate enemas in the treatment of ulcerative proctitis. Aliment Pharmacol Ther 4:557-581, 1990
5. 5. Pullan RD, Ganesh S, Mani V, Evans BK, Williams GT, Rhodes J: Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: A controlled trial. Gut 34:676-679, 1993
6. 6. Gionchetti P, Campieri M, Rizzello, et al: Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis. Aliment Pharmacol Ther 11:673-678, 1997
7. 7. Morris GP, Beck PL, Henidge MS, Depew WT, Szewzcuk MR, Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795-803, 1989
8. 8. Messori A, Brignola C, Trallori T, et al: Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: A Meta-analysis. Am J Gastroenterol 89:692-698, 1994
9. 4 synthesis. Gastroenterology 102:18-27, 1992
10. 10. Vilaseca J, Salas A, Guarner F, Rodriguez R, Martinez M, Malagelada JR: Fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. Gut 31:539-544, 1990
11. 11. Fries W, Pagiaro E, Canova E, Carraro P, Gasparini G, Pomerri F, Martin A, Carlotto C, Mazzon E, Sturniolo G, Longo G: The effect of heparin on trinitrobenzene sulphonic acid induced colitis in the rat. Aliment Pharmacol Ther 12:229-236, 1998
12. 12. Burford N, Veldhuyzen van Zanten SJO, Agocs L, et al: Anti-Helicobacter pylori properties of new bismuth compounds. Gastroenterology 106:A59, 1994
13. 13. Sandha GS, LeBlanc R, Veldhuyzen van Zanten SJO, Sitland TD, Agocs L, Burford N, Best L, Mahoney D, Huffman D, Leddin DJ: Chemical structure of bismuth compounds determines their gastric healing efficacy and anti-Helicobacter pylori activity. Dig Dis Sci 43:2727-2732, 1998
14. 14. Peterson TC, Davey K: Effect of acute pentoxifylline in an experimental model of colitis. Aliment Pharmacol Ther 11:575-580, 1997
15. 15. Higa A, McKnight GW, Wallace JL: Attenuation of epithelial injury in acute experimental colitis by immunemodulators. Eur J Pharmacol 239:171-176, 1993
16. 16. Fine K, Lee E: Efficacy of open label bismuth subsalicylate for the treatment of microscopic colitis. Gastroenterology 114:29-36, 1998
17. 17. Marshall BJ: The use of bismuth in gastroenterology. Am J Gastroenterol 86:16-25, 1991
18. 18. Tilman LA, Drake FM, Dickson JS, Wood JR: Safety of bismuth in the treatment of gastrointestinal diseases. Aliment Pharmacol Ther 10:459-467, 1996
19. 19. Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, Ehrhardt R, Neurath M: Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol Today 18(2):61-64, 1997
20. 20. Ribbons KA, Thompson JH, Liu X, Pennline K, Clarke D, Miller M: Anti-inflammatory properties of interleukin 10 administration in hapten-induced colitis. Eur J Pharmacol 323:245-254, 1997
21. 21. Neurath M, Pettersson S, Mayer-Zum-Buschenfelde K, Strober W: Local administration of antisense phosphorothioate oligonucleotides to the p-65 sub unit of NF-kappaB abrogates established experimental colitis in mice. Nature Med 2:998-1004, 1996
22. 22. Garcia-Lafuente A, Antolin M, Guarner F, Crespo E, et al: Incrimination of anerobic bacteria in the induction of experimental colitis. Am J Physiol 272:G10-G15, 1997
23. 23. Lambert JR, Midolo P: The actions of bismuth in the treatment of Helicobactor pylori infection. Aliment Pharmacol Ther 11(suppl 1):27-33, 1997